Show summary Hide summary
A fresh review of clinical trials suggests the muscle supplement creatine could ease symptoms for some people with depression — but researchers say the evidence is mixed and far from decisive. The analysis highlights potential benefits when creatine is used alongside standard treatments, while underlining the need for larger, more rigorous studies.
What the review examined
Researchers in Canada pooled results from five randomized controlled trials to evaluate whether creatine monohydrate affects mood disorders. Four trials focused on people with major depressive disorder, and one assessed individuals with bipolar disorder who were experiencing a depressive episode.
China clamps down on AI companions: users scramble as services disappear
Cleveland signs Mario Hezonja: unmistakable shift in post-LeBron era
The studies varied in design: participants included adult women, teenage girls and mixed groups; dosages ranged from about 5 to 6 grams per day; and follow-up periods were typically six to eight weeks. Those differences help explain why the trials produced inconsistent outcomes.
Key findings
Across the small set of trials, the overall picture was uneven.
- Positive signals: In one trial, women taking 5 g of creatine daily in addition to the antidepressant escitalopram showed greater symptom improvement at eight weeks. Another study reported benefits when creatine supplemented cognitive behavioral therapy.
- No clear effect: Trials involving adolescent girls and a study of bipolar depression (6 g daily added to medication) did not demonstrate meaningful improvement over the comparison groups.
- Safety: Adverse effects were generally mild, most commonly brief stomach upset; authors described creatine as having a favorable safety profile in otherwise healthy adults.
Why this matters now
Interest in creatine stems from its role in cellular energy production. Several brain-imaging and biochemical studies suggest people with mood disorders may process creatine differently, and researchers theorize that optimizing brain energy metabolism could influence depressive symptoms. If true, creatine would represent a low-cost, widely available option to be used in addition to standard care.
Expert perspective
Bassam Jeryous Fares, a medical student involved in the review, said the pattern of results is “intriguing but inconclusive” — a signal that justifies further research rather than a basis for changing clinical practice. The corresponding author, psychiatry resident Nicholas Fabiano, noted the supplement’s tolerability in the trials but urged caution about generalizing findings.
Dr. Thea Gallagher, a psychologist who directs wellness programs at NYU Langone, emphasized that creatine should be viewed as a possible complement to evidence-based treatments — not a replacement. She pointed out that antidepressant medication, psychotherapy, regular exercise and good sleep remain the foundation of care for most people with depression.
Limitations and next steps
The review synthesizes existing trials rather than presenting new experimental data, and the small number of studies limits confidence in the conclusions. Heterogeneity in participant age, diagnosis, dosing and study length makes it difficult to identify who might benefit most or what an optimal regimen would look like.
- Research gaps: Larger, well-controlled trials are needed to confirm effects, define which patient subgroups are most likely to respond, and establish safe, effective dosing.
- Clinical caution: People with kidney disease, pregnant individuals, or those with other significant medical conditions should consult a clinician before starting creatine.
Practical takeaways
For now, the evidence places creatine firmly in the category of a potential adjunctive option rather than a proven treatment. Clinicians and patients curious about trying it should weigh current data, consider individual health risks, and maintain established therapies while any supplement is being trialed.
Bottom line: Creatine shows promise as an add-on to conventional depression care for some groups, but inconsistent trial results and limited sample sizes mean it is not yet a recommended standalone treatment. Further clinical trials will be necessary to move from preliminary signals to clear guidance.
